Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: EXELON

« Back to Dashboard
Exelon is a drug marketed by Novartis and is included in three NDAs. It is available from four suppliers. There are two patents protecting this drug and four Paragraph IV challenges.

This drug has thirty-two patent family members in twenty-six countries.

The generic ingredient in EXELON is rivastigmine. There are twenty-seven drug master file entries for this compound. Three suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the rivastigmine profile page.

Summary for Tradename: EXELON

Patents:2
Applicants:1
NDAs:3
Suppliers: see list4

Pharmacology for Tradename: EXELON

Clinical Trials for: EXELON

Rivastigmine and Huperzine A as Treatments for Cocaine Dependence
Status: Completed Condition: Cocaine Dependence; Cocaine Addiction; Cocaine Abuse; Substance Abuse

Rivastigmine as a Treatment for Methamphetamine Dependence
Status: Completed Condition: Methamphetamine Dependence; Substance Abuse; Methamphetamine Abuse

A Double-Blind, Placebo-controlled Crossover Study of Repeat Rivastigmine Administration in Healthy Male Volunteers
Status: Completed Condition: Rivastigmine Toxicity

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
Status: Completed Condition: Alzheimer's Disease

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
Status: Completed Condition: Alzheimer Disease

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
Status: Completed Condition: Parkinson's Disease Dementia

A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
Status: Completed Condition: Alzheimer's Disease

Exelon Patch and Combination With Memantine Comparative Trial
Status: Completed Condition: Alzheimer's Disease

Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients
Status: Completed Condition: Alzheimer Disease

Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients
Status: Recruiting Condition: Alzheimer's Disease

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
EXELON
rivastigmine tartrate
SOLUTION;ORAL021025-001Apr 21, 2000DISCNNo<disabled><disabled>
Novartis
EXELON
rivastigmine
FILM, EXTENDED RELEASE;TRANSDERMAL022083-001Jul 6, 2007RXNo6,335,031<disabled>Y<disabled>
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-005Apr 21, 2000RXNo<disabled><disabled>
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-003Apr 21, 2000RXYes<disabled><disabled>
Novartis
EXELON
rivastigmine
FILM, EXTENDED RELEASE;TRANSDERMAL022083-005Aug 31, 2012RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: EXELON

Drugname Dosage Strength RLD Submissiondate
rivastigmineTransdermal System Extended-release13.3 mg/24 hrExelon1/22/2013
rivastigmineTransdermal System Extended-release4.6 mg/24 hr and 9.5 mg/24 hrExelon Patch4/27/2011
rivastigmine tartrateOral Solution2 mg/mLExelon11/5/2004
rivastigmine tartrateCapsules1.5 mg, 3 mg, 4.5 mg and 6 mgExelon4/21/2004

International Patent Family for Tradename: EXELON

Country Document Number Publication Date
Norway20003472Jul 05, 2000
Slovakia10532000Nov 07, 2000
China1129427Dec 03, 2003
Czech Republic20002557Oct 11, 2000
Japan3820103Sep 13, 2006
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc